How CROs Are Innovating Clinical Trial Site Payments
The recent IQVIA Clinical Trial Site Payments Webcast shed light on the intricacies of financial management in clinical trials,...
BMS’s Opdivo for Lung Cancer: US & EU Filings Accepted
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics Application (sBLA)...
AstraZeneca Grows US Cell Therapy Production Capacity
AstraZeneca has announced a $300 million investment in a new state-of-the-art facility in Rockville, Maryland, aimed at advancing its...
Roche on RBQM and AI in Clinical Trials: Secrets to Success
In this interview, Michael Torok, Head of Quality Assurance Programs at Roche, delves into the operationalization of RBQM (Risk...
Participant Payments Pulse Check: How and Why to Prioritize Your Strategy
In this exclusive interview, we sit down with Donna Libretti Cooke, JD, a distinguished clinical operations specialized consultant known...
Advancing ClinOps Excellence: The 15th Annual SCOPE Summit 2024
Join us at the 15th Annual SCOPE Summit, scheduled for February 11-14, 2024, in Orlando, Florida, at the Rosen...
Sloan Kettering’s Clinical Trial EHR Integration: A New Era Unveiled
In an era in which the White House Office of Science and Technology Policy emphasizes the need for a...
ICON Survey Stresses Combo Therapies in Obesity Care
ICON plc conducted an industry survey of over 100 professionals engaged in obesity-related clinical research, revealing expectations for the...
Gilead Evoke-01 Phase 3 Study: Critical Update Issued
Gilead Sciences, Inc. announced that the Phase 3 EVOKE-01 study, which evaluated Trodelvy® (sacituzumab govitecan-hziy; SG) against docetaxel in...
8-Year Data: BMS Opdivo & Yervoy Outperform in RCC Survival
Bristol Myers Squibb (BMS) announced that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) continues to show significant long-term...